https://www.selleckchem.com/ALK.html
6years; 49.0% female). A total of 61% of patients (TD, 66%; TF, 58%) discontinued eculizumab, with TD patients having a shorter median time to discontinuation (TD, 0.5years; TF, 0.9years). TD patients had more all-cause hospitalizations than TF patients (p 0.05). TD patients incurred higher all-cause direct medical costs (adjusted cost difference = $247,848) and medical-related absenteeism costs (adjusted cost difference = $4186) than TF patients (all p 0.05), largely driven by hospitalizations. Similar trends were observed for PNH-related
Like
Comment
Share
